A carregar...
A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease
BACKGROUND: Mild cognitive impairment in Parkinson's disease (PD‐MCI) is associated with diminished norepinephrine from the locus coeruleus to the prefrontal cortex. Atomoxetine is a specific norepinephrine reuptake inhibitor that has been approved by the US Food and Drug Administration to trea...
Na minha lista:
| Publicado no: | Mov Disord Clin Pract |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6174374/ https://ncbi.nlm.nih.gov/pubmed/30363371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12455 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|